Answers are grounded in this paper and cite their sources.
Exosomal miRNAs are emerging as attractive liquid-biopsy biomarkers because of their stability, specificity, and association with cancer progression. Microfluidic technologies can improve multiplex exosomal miRNAs analysis by reducing sample consumption, organizing parallel reactions, integrating extracellular-vesicle enrichment and lysis, and enabling on-chip signal decoding. This review critically compares three implementation routes-spatial encoding, bead-based encoding, and in situ detection-with emphasis on the experimentally demonstrated multiplexing level rather than theoretical coding capacity. Representative studies are compared by analyte scope, microfluidic function, target number, limit of detection, sample type, and clinical validation. Studies using total circulating miRNAs, cell or tissue lysates, non-miRNA exosomal cargoes, or in vivo imaging are explicitly identified as technology-transfer examples rather than direct demonstrations of microfluidic multiplex exosomal miRNA profiling. The remaining challenges include harmonized reporting, scalable on-chip sample preparation, robust decoding, and validation in independent clinical cohorts.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: